Clinical Trial

Danazol for Treatment of Cytopenias in Patients With Cirrhosis

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a phase II pilot study designed to assess the safety and efficacy of danazol for treatment of cytopenias in patients with CPC A/B cirrhosis. Subjects with or without telomere mutations and/or shortened telomeres will be treated with danazol 600 mg per day by mouth for a duration of 24 months. The goal will be to treat a total of 10 patients.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2021-04-29; most recent amendment 2025-07-09.
Status change: Not Yet Recruiting → Recruiting 2023-04-19
Trial Details
NCT Number NCT04873102
Lead Sponsor University of Southern California
Conditions Cirrhosis, Liver, Cytopenia
Enrollment 10 participants
Start Date 2024-08-01
Primary Completion 2027-08-01 (estimated)
Study Completion 2027-08-01 (estimated)
Updated on ClinicalTrials.gov 2025-07-11